__timestamp | Blueprint Medicines Corporation | Corcept Therapeutics Incorporated |
---|---|---|
Wednesday, January 1, 2014 | 7890000 | 34916000 |
Thursday, January 1, 2015 | 14456000 | 36949000 |
Friday, January 1, 2016 | 19218000 | 45240000 |
Sunday, January 1, 2017 | 27986000 | 62416000 |
Monday, January 1, 2018 | 47928000 | 81289000 |
Tuesday, January 1, 2019 | 96388000 | 100359000 |
Wednesday, January 1, 2020 | 157743000 | 105326000 |
Friday, January 1, 2021 | 195293000 | 122356000 |
Saturday, January 1, 2022 | 237374000 | 152848000 |
Sunday, January 1, 2023 | 295141000 | 184259000 |
Monday, January 1, 2024 | 359272000 |
Unleashing insights
In the competitive world of biotechnology, managing expenses is crucial for sustainable growth. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Blueprint Medicines Corporation and Corcept Therapeutics Incorporated from 2014 to 2023. Over this period, Blueprint Medicines saw a staggering increase of over 3,600% in SG&A expenses, reflecting its aggressive expansion and investment in operational infrastructure. In contrast, Corcept Therapeutics experienced a more modest rise of approximately 430%, indicating a steady but cautious growth strategy.
By 2023, Blueprint Medicines' SG&A expenses were nearly 60% higher than Corcept's, highlighting its commitment to scaling operations. This trend underscores the differing strategic priorities of these companies, with Blueprint focusing on rapid growth and Corcept maintaining a balanced approach. Investors and industry analysts should consider these trends when evaluating the financial health and strategic direction of these biotech firms.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated Trends and Insights
Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated: SG&A Expense Trends
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Rhythm Pharmaceuticals, Inc.
Corcept Therapeutics Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Corcept Therapeutics Incorporated and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc. Trends and Insights